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Abstract: Brooke–Spiegler syndrome (BSS; OMIM 605041) is an
autosomal dominant disease characterized by skin appendage
tumors due to mutations in the cylindromatosis gene (CYLD).
We investigated a Hungarian BSS pedigree with two affected
members, father and daughter. Direct sequencing demonstrated a
novel missense mutation (c.2613C>G; p.His871Gln) in exon 19
within the ubiquitin-specific protease domain of the encoded
protein. We performed preliminary analysis to reveal the
functional role of this novel mutation. Our data suggest that this
novel CYLD mutation leads to increased ubiquitination of NEMO
through influencing deubiquitinating activity of the CYLD protein
and thus may result in enhanced NF-jB signalling.
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Background
Brooke–Spiegler syndrome (BSS; OMIM 605041) has been
described as an autosomal dominant disease characterized by the
development of a wide variety of skin appendage tumors, such as
cylindromas, trichoepitheliomas and spiradenomas (1,2).
The gene responsible for BSS, the cylindromatosis gene
(CYLD), is localized at 16q12-q13 (2). So far 86 mutations have
been identified, mainly at the 3′ end of the CYLD gene (exons
8–20; 3–9). These mutations have been identified in patients with
phenotypic features of either BSS, familial cylindromatosis
(OMIM 132700) or multiple familial trichoepithelioma type 1
(OMIM 601606; 10).
The CYLD gene codes for a cysteine protease type deubiquitin-
ase, which directly interacts with and deubiqutinates TRAF2,
TRAF6 (TNF receptor-associated factors) and NEMO (IKBKG; an
inhibitor of the kappa light polypeptide gene enhancer in B cells,
kinase gamma; 11–13). Thus, CYLD attenuates TNF-a-induced
classical NF-jB signalling leading to programmed cell death
(14,15). Reduced CYLD activity results in an elevated activity of
NF-jB and hence increased resistance to apoptosis and carcino-
genesis (14,15). Through the deubiquitination of the dishevelled
protein, CYLD can also influence WNT/b-catenin signalling (16).
Questions addressed
This study reports a novel missense mutation on the CYLD gene
in a Hungarian family with BSS, which by influencing the deubi-
quitination activity of CYLD leads to increased ubiquitination of
NEMO.
Experimental design
A pedigree from the Southern part of Hungary (Szeged region)
affected by BSS was investigated. The pedigree has two affected
and five unaffected individuals spanning two generations. One of
the affected individuals, a 60-year-old man (I-1), has numerous
soft, hairless, skin-coloured papules around his nose, in his ears,
on his scalp and on his shoulders (Fig. 1a–d). Some of the tumors
in the head and neck region were surgically removed. His daugh-
ter (II-2), a 35-year-old woman, presented with milder symptoms.
Routine histological examination of the excised tumors suggested
the diagnosis of the BSS. Internal cancer, parotoid tumors or
other malignancies were not present in the history of these
patients. Written informed consents were obtained from the
enrolled patients and controls according to a protocol approved
by the Local Ethics Committee in adherence to the Helsinki
guidelines.
Materials and methods can be found in the Supporting
information.
Results and discussion
Mutation analysis with direct sequencing of the coding region of
the CYLD gene revealed a novel missense mutation (c.2613C>G p.
His871Gln), located in exon 19 in heterozygous form in both
affected patients (Fig. 1e). This mutation could not be identified
in any of the clinically unaffected family members or in the
screened 95 Hungarian generally healthy controls (Fig. 1f). The
mutation is situated in a highly conserved region of the CYLD
gene (Fig. 2b), encoding a histidine-box structure, which is part
of a larger structure forming the ubiquitin-specific protease (USP)
domain. This novel mutation leads to a change from histidine to
glutamine at position 871. Interestingly, this position in the amino
acid sequence change is localized within an active site where
phosphorylation takes place (www.uniprot.org; Accession No:
Q9NQC7), suggesting a putative role for this amino acid change
in the function of the USP domain. To note, another mutation at
the same amino acid position (c.2611C>A p.His871Asn) induced
by in vitro mutagenesis has been functionally characterized: the
functional data indicated impairment in the deubiquitinase
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activity of CYLD protein in vitro, demonstrated by its reduced
enzymatic activity (14).
To reveal the function of this novel mutation, we studied the
known CYLD-regulated pathways. As CYLD is known to directly
interact with the NF-jB signalling NEMO protein, the expression
of NEMO was determined and found to be significantly reduced in
the CD4+ T lymphocytes of the patients compared to healthy con-
trols (data not shown). Our preliminary data suggest that decreased
NEMO expression is associated with its altered deubiquitination,
NEMO immunoprecipitated from fibroblasts carrying the CYLD
mutation demonstrated significantly higher ubiquitination than
NEMO immunprecipitated from control fibroblasts (Figure S1).
As it is known that CYLD protein is expressed in nearly every
human tissue with the highest expression level in the CD4+ and
CD8+ lymphocytes and CYLD deficiency can lead to defects in
T-cell maturation and B-cell responses (17–25), however, others
reported on normal T- or B-cell phenotype (24,26,27). We charac-
terized peripheral blood lymphocytes in patients with BSS, but
only minor alterations were observed (data not shown).
We also investigated whether the newly identified mutation affects
the WNT/b-catenin pathway as it has been recently suggested as one
of the functions of CYLD protein (16). For that, we performed
immunohistochemical detection of the translocation of b-catenin in
the tissue samples of patient I-1, but found no alteration in the
intracellular distribution of b-catenin (data not shown).
We identified here a novel mutation (c.2613C>G p.His871Gln)
of CYLD in a Hungarian BSS pedigree. Identification of the
underlying mutation may have a considerable impact on family
planning because it offers the possibility of prenatal mutation
screening. Our functional studies revealed a decreased NEMO pro-
tein level in the CD4+ T lymphocytes of the patients compared to
healthy controls. As in the literature, there is evidence that CYLD
can decrease the ubiquitination of NEMO, but there are no data
suggesting that CYLD can influence the expression level of the
NEMO protein, we have measured its ubiquitination after immu-
noprecipitation and found an increased level of ubiquitination of
the NEMO protein in fibroblasts carrying the novel CYLD muta-
tion. However, it is well known that CYLD removes only the
Lys63-linked polyubiquitin chain taking part in the proteosomal-
independent cellular processes (11), and it has been recently
reported that 26S proteasome can degrade Lys63-linked ubiquitin
substrates (27) raising the possibility that the Lys63-linked ones
can also serve as a targeting signal for proteaseomal degradation.
Based on our results, we suppose that this novel mutation
through the increased ubiquitination of NEMO leads to decreased
NEMO expression and as a consequence may influence the NF-jB
pathway. Further studies are needed to elucidate the exact mecha-
nism of the development of BSS symptoms. As BSS displays only
skin tumors, and mainly appendageal tumor formations, it may









Figure 1. (a) Numerous skin-coloured, dome-shaped tumors are present around
the nose, (b) in the retroauricular region (c, d) and in the ears of patient z-1.
(e) The DNA sequence of patient I-1 shows a heterozygous single nucleotide
substitution c.2613C>G, which converts codon 871 CAC for histidine to CAG for
glutamine; this mutation is designated p.His871Gln. The same mutation was found
in patient II-2. (f) Wild-type sequence of genomic DNA spanning codons 868–874
of the CYLD gene.
(a)
(b)
Figure 2. (a) The investigated Hungarian pedigree has two clinically affected
individuals, who were heterozygous for the c.2613C>G p.His871Gln mutation;
all the other family members were clinically unaffected and carried only wild-type
alleles. (b) Comparison of the sequences of the CYLD gene among different
species demonstrated that the c.2613C>G p.His871 mutation is located in a highly
conserved region, which forms part of a histidine box.
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Figure S1. NEMO was immunoprecipitated from
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Abstract: In contact hypersensitivity (CHS), multiple cells,
inflammatory mediators and cytokines are known to be involved
in the regulation of the immune response. Previously, we
revealed the reactive oxygen species generation by 2, 4,
6-trinitrobenzene sulphonic acid (TNBS) in vivo, followed by
heat shock protein 70 (Hsp70) carbonylation and the exogenous
antioxidant role of cell-permeable Hsp70. Here, we demonstrate
the role of Hsp70 using cell-permeable Hsp70 in the mouse CHS
model. Pretreatment of cell-permeable Hsp70: (i) suppressed ear
swelling; (ii) down-regulated phosphorylated p38, but up-
regulated phosphorylated extracellular signal-regulated kinase;
(iii) increased population of CD4+CD25+Foxp3+ T cells; (iv)
decreased secretion of tumor necrosis factor-a (TNF-a), IL-12,
interferon-c and IL-2 and (v) but up-regulated IL-4 and
transforming growth factor beta (TGF-b) in the lymph nodes. In
conclusion, cell-permeable Hsp70 attenuates CHS through
modulation of MAPK pathway and regulation of Th1, Th2 and
regulatory T cells.
Key words: allergic contact dermatitis, heat shock protein70, inflamma-
tory cytokines, protein transduction domain
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Background
Allergic contact dermatitis (ACD) is related to the development of
contact hypersensitivity (CHS). ACD is divided into a sensitization
phase and a challenge phase (1). Recently, a few reports have
revealed the generation of reactive oxygen species (ROS) in CHS
by dendritic cells (DCs) (2) and keratinocytes (3). Previously, the
ROS generation by 2, 4, 6-trinitrobenzene sulphonic acid (TNBS)
in mouse DCs, XS-106 DCs followed by ATP synthase carbonyla-
tion was demonstrated (4). Furthermore, we verified the carbony-
lation of heat shock protein 70 (Hsp70) and an antioxidant effect
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